Navigation Links
More evidence on benefits of high blood pressure drugs in diabetic eye disease
Date:2/24/2010

Scientists in Massachusetts are reporting new evidence that certain high blood pressure drugs may be useful in preventing and treating diabetic retinopathy, the leading cause of vision loss in people with diabetes. The study, the largest to date on proteins in the retina, could lead to new ways to prevent or treat the sight-threatening disease, they say. The findings are in ACS' Journal of Proteome Research, a monthly publication.

Edward Feener and colleagues point out that diabetic retinopathy is a common complication of diabetes, which affects millions of people worldwide. It involves damage to blood vessels in the retina, the light sensitive tissue in the back of the eye. Previous studies suggested that drugs used to treat high blood pressure, including ACE inhibitors and angiotensin receptor blockers (ARBs), may help prevent the condition.

The scientists analyzed proteins from the retinas laboratory mice with normal blood pressure and diabetes and compared them to those of non-diabetic mice. They identified 65 abnormal proteins in the diabetic mice out of more than 1,700 proteins in the study. Treatment with the ARB medication, candesartan, prevented the abnormal changes in more than 70 percent of the proteins.


'/>"/>

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society
Source:Eurekalert  

Page: 1

Related biology news :

1. Retail meat linked to urinary tract infections: Strong new evidence
2. First evidence that blueberry juice improves memory in older adults
3. Research adds to evidence that autism is a brain connectivity disorder
4. More evidence on benefits of high blood pressure drugs in diabetic eye disease
5. New evidence that dark chocolate helps ease emotional stress
6. Does green tea prevent cancer? Evidence continues to brew, but questions remain
7. Algae and pollen grains provide evidence of remarkably warm period in Antarcticas history
8. Growing outcomes evidence spurs renewed interest in unique heart valve procedure
9. Researchers find first evidence of virus in malignant prostate cells
10. Growing evidence of marijuana smokes potential dangers
11. First direct evidence of substantial fish consumption by early modern humans in China
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
More evidence on benefits of high blood pressure drugs in diabetic eye disease
(Date:8/12/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is proud to announce that iMedNet ... platform, has led the way to significant and unprecedented ...   Q2 2015 and Q1 2015 were, respectively, the ... sold in the company,s 15 year history.  In addition, ...
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, featuring FPC,s ... in 2015 that relate to sales of FPC1155 for this smartphone ... MSEK for 2015. Jörgen Lantto, CEO of FPC, comments: ... smartphone manufacturer in China and we are ... for Z1 , its ...
(Date:8/6/2015)... , August 6, 2015 ... (SMI) shows the world,s first Eye Tracking Integration ... Moverio BT-200 see-through head mounted display and on SMI,s ... quality and efficiency is brought to personalized visualization and ... first time, professionals and researchers can integrate gaze, and ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... LAS VEGAS , Oct. 7, 2013 ValidSoft, ... and transaction verification solutions, and a wholly owned subsidiary ... integrated its secure mobile commerce technology with Spindle,s new ... the Money2020 ( www.money2020.com ) conference being held from ...
... SAN DIEGO , Oct. 9, 2013  Biocom, the association ... community, today announced the endorsement of Nathan Fletcher ... . (Logo: http://photos.prnewswire.com/prnh/20130228/LA69104LOGO ) "A ... of the three major candidates.  Although all three would be ...
... SAN DIEGO , Oct. 14, 2013 Trovagene, ... cell-free molecular diagnostics, announced today that two abstracts (#B175 ... novel, non-invasive cancer mutation monitoring platform will be presented ... on Molecular Targets and Cancer Therapeutics in ...
Cached Biology News:ValidSoft and Spindle to Demo New Mobile Commerce Ecosystem at Money2020 2ValidSoft and Spindle to Demo New Mobile Commerce Ecosystem at Money2020 3ValidSoft and Spindle to Demo New Mobile Commerce Ecosystem at Money2020 4ValidSoft and Spindle to Demo New Mobile Commerce Ecosystem at Money2020 5Biocom Announces 2013 San Diego Mayoral Primary Endorsement 2Trovagene Announces Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference 2Trovagene Announces Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference 3
(Date:8/27/2015)... Irvine, CA (PRWEB) , ... August 27, 2015 ... ... leader in Personalized Medicine, recently presented new data on the relationship of genetics ... 2015 20th World Congress on Heart Disease in Vancouver, British Columbia, Canada. The ...
(Date:8/26/2015)... Aug. 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended June 30, ... Canadian dollars and presented under International Financial Reporting ... with respect to our Oral Amp B program, ... manufacturer," said Andrew Rae , President & ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... investment in the development and manufacture of highly valued cardiac markers used in ... team's extensive expertise with protein chemistry has led to the development and commercialization ...
(Date:8/26/2015)... FRANCISCO , Aug. 26, 2015  Platform ... that it has received a $1.5M Phase II ... (NIH) to further develop its therapeutic agent to ... clinical need in end stage renal disease (ESRD) ... the National Institute of Diabetes and Digestive and ...
Breaking Biology Technology:Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
... CRANBURY, N.J., March 7, 2012 Palatin Technologies, Inc. (NYSE ... presenting at the 24th Annual ROTH OC Growth Stock Conference ... The conference will be held at the Ritz Carlton Laguna ... Ph.D., President and Chief Executive Officer of Palatin Technologies, will ...
... LONGNAN CITY, China, March 6, 2012   Apexigen, Inc., ... Biological Pharmaceutical Co., Ltd. (GDBP), which is listed ... they entered into a collaboration to grant an ... APX004 in China.   APX004 is a humanized monoclonal ...
... Drexel University,s Dr. Yury Gogotsi has given the engineering ... the electrodes of supercapacitors the low-cost, lightweight energy ... other applications. In a piece published in the March ... his collaborators from universities in France and England, take ...
Cached Biology Technology:Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004 2Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004 3Drexel's Gogotsi and team advance understanding of energy storage mechanisms in Nature Materials 2
... 2500ml narrow mouth PYREX low form culture flask is ... to volume ratio. This flask has a heavy beaded ... marking spot. The neck O.D. is 38mm and takes ... use this flask on a heat source smaller than ...
... is designed to allow ampicillin selection in ... driving the gene for ampicillin resistance is ... promoter. It mediates higher transcription efficiency than ... polyadenylation signal terminates the ampicillin expression. The ...
... Pyronin Y is most widely used ... selectively and differentially stain nucleic acids ... dichromatic dye solution, Pyronin Y stains ... DNA green. Chem comp: ...
... a magnetic bead-based PCR purification ... transfer, centrifugation or filtration steps. ... large PCR extension products in ... AMPure can easily be performed ...
Biology Products: